This is a news story, published by Ars Technica, that relates primarily to FDA news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Ars Technica, you can click here:
more news from Ars TechnicaOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
oral phenylephrine. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest nasal decongestant news, phenylephrine news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
counter decongestantArs Technica
•
78% Informative
The FDA formally began the process of abandoning oral phenylephrine, a common over-the-counter decongestant.
The agency concluded last year that the drug is not effective at relieving stuffy noses.
For now, the FDA has issued a proposed order to remove oral Phenylephrine from the list of drugs that drugmakers can include.
VR Score
81
Informative language
82
Neutral language
49
Article tone
formal
Language
English
Language complexity
58
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links